報價延遲最少15分鐘:2025/04/12 05:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.75 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.12/-0.79
|
|
企業價值
776.07M
|
| 資產負債 |
|
每股賬面淨值
1.81
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/04/12 05:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. |